Notably, the survival analysis indicated that cancer patients with concomitantly high expression of p-RB, p-USP51, and ZEB1 in their tumors had shorter overall survival than those with low p-RB, p-USP51, and ZEB1 expression (Fig. 6h–j). Here, USP51 is linked to cancer.